PCRX Pacira BioSciences, Inc.
Stock Price & Overview

$14.53-0.16 (-1.09%)4:00 PM 09/20/24
NASDAQ | $USD | Post-Market: $14.76 +0.23 (+1.58%) 4:39 PM

PCRX Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close

Quant Ranking

Ratings Summary

People Also Follow

Similar to PCRX

ETFs Holding PCRX

PCRX Company Profile

Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Employees
712
Founded
2006
Address
  • 5401 West Kennedy Boulevard
  • Suite 890
  • Tampa, FL, 33609
  • United States
Phone Number
813 553 6680

PCRX Revenue

PCRX Earnings Per Share

Earnings Estimates

Earnings Revisions

Valuation

Growth

Profitability

Momentum

Capital Structure

Dividends

PCRX Ownership

PCRX Peers

Risk

Technicals

PCRX Transcripts

Investor Presentations

PCRX SEC Filings

PCRX Income Statement

PCRX Balance Sheet

PCRX Cash Flow Statement

PCRX Long Term Solvency

Discover More

You may be interested in:

Pacira BioSciences, Inc. (PCRX) Frequently Asked Questions